Skip to main content
ALLIANCE PHARMA PLC logo

ALLIANCE PHARMA PLC — Investor Relations & Filings

Ticker · APH ISIN · GB0031030819 LEI · 213800RYIWZA4Q5WPZ13 IL Wholesale and retail trade
Open in API
Filings indexed 492 across all filing types
Latest filing 2018-01-02 Regulatory Filings
Country GB United Kingdom
Listing IL APH

About ALLIANCE PHARMA PLC

https://www.alliancepharmaceuticals.com/

Alliance Pharma PLC is an international specialty pharmaceutical company with a primary focus on consumer healthcare. The company's business model is centered on the acquisition, licensing, and marketing of a portfolio of consumer health products and prescription medicines. It operates globally, investing in its key brands to empower consumers to improve their health and wellbeing. A core part of its strategy is the ongoing development to become a high-performing consumer healthcare company.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is a notification filed with the RNS (Regulatory News Service) on January 2, 2018, regarding the 'Total Voting Rights' of Alliance Pharma PLC as of December 29, 2017. This type of announcement, which provides a mandatory regulatory update on the total number of shares and voting rights (often used as the denominator for shareholder notifications under FCA rules), does not fit neatly into the specific categories like 10-K, ER, or DIV. It is a general regulatory disclosure. Since it is a specific regulatory announcement that doesn't match other primary categories, the most appropriate classification is the general regulatory filing category, RNS, which serves as a fallback for miscellaneous regulatory announcements.
2018-01-02 English
Block Listing Six Monthly Return
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number : 6116A' header, indicating it is a filing distributed via the Regulatory News Service (RNS). The content details a 'Block Listing Six Monthly Return' for Alliance Pharma PLC, covering the period from June 28, 2017, to December 28, 2017. This return reports on the status of shares under various share option plans, including the number allotted and the remaining balance. While it contains specific financial/share data, its primary function is a mandatory regulatory disclosure distributed through the RNS system, rather than a comprehensive report (like 10-K or IR) or a specific announcement like a dividend (DIV) or management change (MANG). Given the structure and the explicit RNS identifier, the most appropriate classification is the general regulatory filing category.
2018-01-02 English
Completion of acquisition of Vamousse
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 3992A' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange'. This strongly indicates it is a regulatory news service announcement. The content details the completion of an acquisition and an executive appointment, which are material events requiring immediate disclosure. Since this is a general regulatory announcement that doesn't fit the specific categories like M&A (TAR), Management Change (MANG), or Capital Change (CAP), the most appropriate general regulatory filing category is RNS.
2017-12-28 English
Block Listing Six Monthly Return
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number (1206A) and contains a 'Block Listing Six Monthly Return' for Alliance Pharma PLC, covering the period from June 28, 2017, to December 28, 2017. This filing details the status of securities under various share option plans, including the number of securities admitted, allotted, and the remaining balance. This type of specific, periodic regulatory update, especially one identified by the RNS system, fits best under the general 'Regulatory Filings' category, as there is no specific code for a 'Block Listing Return' among the provided options. It is not an earnings release (ER), an annual report (10-K), or a capital change announcement (CAP) in the sense of fundraising, but rather a compliance filing related to existing share schemes.
2017-12-22 English
Proposed acquisition of Vamousse
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date '04 December 2017', indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details a 'Proposed acquisition of Vamousse®' by Alliance Pharma PLC, including financial terms (initial consideration, deferred contingent consideration), funding sources (RCF drawdown), and the expected impact on financial ratios. This structure—a formal announcement of a significant corporate action (M&A) released through an official news service—is characteristic of a general regulatory filing. Since the document is an announcement of a transaction rather than a detailed report on M&A activity (TAR) or a general regulatory filing fallback (RNS), and given the context of M&A activity being announced via RNS, the most fitting specific category is M&A Activity (TAR) if the document provided the full details of the transaction, or RNS if it's just the initial notification. However, the content is specifically about a takeover/acquisition proposal, which aligns strongly with the definition of M&A Activity (TAR). Since it is a formal announcement of a transaction, TAR is more specific than the general RNS fallback. The length (5448 chars) is substantial enough to be the primary announcement, not just a brief notice of publication (RPA).
2017-12-04 English
Acquisition of AmetopT
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated '01 December 2017'. It announces a specific corporate action: the acquisition of rights to a product (Ametop) for a defined consideration, including details on funding and financial impact (debt/EBITDA ratio). This format is characteristic of a regulatory news service announcement, often used for material, non-periodic information that must be disclosed promptly. Since the content is a specific corporate event announcement (M&A activity) but is presented via the RNS system, and it is not a full report (like 10-K or IR), the most appropriate classification is 'Regulatory Filings' (RNS) as the general disclosure mechanism, or potentially 'M&A Activity' (TAR). Given the structure strongly emphasizes the RNS dissemination system ('RNS Number', 'This information is provided by RNS'), and the content is a specific transaction announcement, RNS is a strong candidate if TAR is too specific for a general announcement format. However, the core event is an acquisition/takeover proposal (TAR). Since TAR specifically covers 'Announcements and documents related to merger proposals or takeover bids', and this is an acquisition, TAR is a better fit than the general RNS fallback, unless the acquisition is extremely minor or routine. Given the detail provided, TAR is the primary event type. If the document were purely a notification that a report was attached, RPA would be used. Here, the announcement *is* the substance of the transaction.
2017-12-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.